|
Volumn 8, Issue 4, 2004, Pages 355-358
|
Is RGS-2 a new drug development target in cardiovascular disease?
|
Author keywords
cGMP dependent protein kinase Type I (PKGI) ; Hypertension; Nitric oxide (NO) relaxation pathway; Regulator of G protein signalling (RGS) 2
|
Indexed keywords
1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE;
ACETYLCHOLINE;
ANGIOTENSIN 1 RECEPTOR;
ANGIOTENSIN 1 RECEPTOR ANTAGONIST;
CANDESARTAN;
CARDIOVASCULAR AGENT;
CYCLIC GMP;
CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR;
ENDOTHELIN 1;
GUANINE NUCLEOTIDE BINDING PROTEIN;
GUANOSINE TRIPHOSPHATASE;
GUANYLATE CYCLASE INHIBITOR;
INOSITOL 1,4,5 TRISPHOSPHATE;
LEUCINE ZIPPER PROTEIN;
NITRIC OXIDE;
NITROPRUSSIDE SODIUM;
NORADRENALIN;
PHENYLEPHRINE;
PROTEIN KINASE;
PROTEINASE;
PROTEINASE ACTIVATED RECEPTOR 1;
RECOMBINANT PROTEIN;
RECOMBINANT RGS PROTEIN 2;
RGS PROTEIN;
RGS2 PROTEIN;
SEROTONIN;
THROMBIN;
THROMBIN RECEPTOR ACTIVATING PEPTIDE;
UNCLASSIFIED DRUG;
ARTICLE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR EFFECT;
DRUG TARGETING;
HYPERTENSION;
MOLECULAR INTERACTION;
MOUSE;
NONHUMAN;
PATHOPHYSIOLOGY;
PROTEIN BINDING;
PROTEIN FUNCTION;
SIGNAL TRANSDUCTION;
VASCULAR SMOOTH MUSCLE;
VASOCONSTRICTION;
VASODILATATION;
VIRUS IMMUNITY;
ANIMALS;
CARDIOVASCULAR DISEASES;
DRUG DELIVERY SYSTEMS;
DRUG DESIGN;
HUMANS;
HYPERTENSION;
MICE;
MICE, TRANSGENIC;
RGS PROTEINS;
|
EID: 4344575064
PISSN: 14728222
EISSN: None
Source Type: Journal
DOI: 10.1517/14728222.8.4.355 Document Type: Article |
Times cited : (8)
|
References (6)
|